{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:44:01Z","timestamp":1791200641522,"version":"4.2.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100013041","name":"Vice-Chancellor for Research, Shiraz University of Medical Sciences","doi-asserted-by":"publisher","award":["30940"],"award-info":[{"award-number":["30940"]}],"id":[{"id":"10.13039\/501100013041","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s11030-025-11114-9","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T06:27:53Z","timestamp":1737527273000},"page":"3293-3303","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Optimizing kinase and PARP inhibitor combinations through machine learning and in silico approaches for targeted brain cancer therapy"],"prefix":"10.1007","volume":"29","author":[{"given":"Alireza","family":"Poustforoosh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"issue":"3","key":"11114_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"key":"11114_CR2","unstructured":"NCI (2021) Cancer statistics"},{"issue":"6","key":"11114_CR3","doi-asserted-by":"publisher","first-page":"4950","DOI":"10.1021\/acs.jmedchem.4c00090","volume":"67","author":"JL Duan","year":"2024","unstructured":"Duan JL, Wang CC, Yuan Y, Hui Z, Zhang H, Mao ND et al (2024) Design, synthesis, and structure-activity relationship of novel pyridazinone-based PARP7\/HDACs dual inhibitors for elucidating the relationship between antitumor immunity and HDACs inhibition. J Med Chem 67(6):4950\u20134976","journal-title":"J Med Chem"},{"key":"11114_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecoenv.2024.117343","volume":"288","author":"Y Lin","year":"2024","unstructured":"Lin Y, Li H, Zheng S, Han R, Wu K, Tang S et al (2024) Elucidating tobacco smoke-induced craniofacial deformities: biomarker and MAPK signaling dysregulation unraveled by cross-species multi-omics analysis. Ecotoxicol Environ Saf 288:117343","journal-title":"Ecotoxicol Environ Saf"},{"issue":"8","key":"11114_CR5","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/ddr.21726","volume":"81","author":"QQ Lu","year":"2020","unstructured":"Lu QQ, Chen YM, Liu HR, Yan JY, Cui PW, Zhang QF et al (2020) Nitrogen-containing flavonoid and their analogs with diverse B-ring in acetylcholinesterase and butyrylcholinesterase inhibition. Drug Dev Res 81(8):1037\u20131047","journal-title":"Drug Dev Res"},{"key":"11114_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2020.113359","volume":"265","author":"V Spiegler","year":"2021","unstructured":"Spiegler V, Greiffer L, Jacobtorweihen J, Asase A, Lanvers-Kaminsky C, Hempel G et al (2021) In vitro screening of plant extracts traditionally used as cancer remedies in Ghana\u201315-Hydroxyangustilobine A as the active principle in Alstonia boonei leaves. J Ethnopharmacol 265:113359","journal-title":"J Ethnopharmacol"},{"issue":"1","key":"11114_CR7","doi-asserted-by":"publisher","first-page":"2195991","DOI":"10.1080\/14756366.2023.2195991","volume":"38","author":"Y Gao","year":"2023","unstructured":"Gao Y, Duan J, Dang X, Yuan Y, Wang Y, He X et al (2023) Design, synthesis and biological evaluation of novel histone deacetylase (HDAC) inhibitors derived from \u03b2-elemene scaffold. J Enzyme Inhib Med Chem 38(1):2195991","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"D1","key":"11114_CR8","doi-asserted-by":"publisher","first-page":"D1151","DOI":"10.1093\/nar\/gkae1008","volume":"53","author":"M Yin","year":"2025","unstructured":"Yin M, Feng C, Yu Z, Zhang Y, Li Y, Wang X et al (2025) sc2GWAS: a comprehensive platform linking single cell and GWAS traits of human. Nucleic Acids Res 53(D1):D1151\u2013D1161","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"11114_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3390\/ph16010037","volume":"16","author":"H Huang","year":"2022","unstructured":"Huang H, Huang F, Liang X, Fu Y, Cheng Z, Huang Y et al (2022) Afatinib reverses EMT via inhibiting CD44-Stat3 axis to promote radiosensitivity in nasopharyngeal carcinoma. Pharmaceuticals 16(1):37","journal-title":"Pharmaceuticals"},{"issue":"2","key":"11114_CR10","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/cjoc.202200406","volume":"41","author":"L Chen","year":"2023","unstructured":"Chen L, Jiang Z, Yang L, Fang Y, Lu S, Akakuru OU et al (2023) HPDA\/Zn as a CREB inhibitor for ultrasound imaging and stabilization of atherosclerosis plaque. Chin J Chem 41(2):199\u2013206","journal-title":"Chin J Chem"},{"key":"11114_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2023.154887","volume":"126","author":"X Cheng","year":"2024","unstructured":"Cheng X, Huang J, Li H, Zhao D, Liu Z, Zhu L et al (2024) Quercetin: a promising therapy for diabetic encephalopathy through inhibition of hippocampal ferroptosis. Phytomedicine 126:154887","journal-title":"Phytomedicine"},{"key":"11114_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.snb.2024.136895","volume":"424","author":"H Wang","year":"2025","unstructured":"Wang H, Yan Z, Yang W, Liu R, Fan G, Gu Z et al (2025) A strategy of monitoring acetylcholinesterase and screening of natural inhibitors from Uncaria for Alzheimer\u2019s disease therapy based on near-infrared fluorescence probe. Sens Actuators B Chem 424:136895","journal-title":"Sens Actuators B Chem"},{"key":"11114_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/cercor\/bhae226","author":"B Shen","year":"2024","unstructured":"Shen B, Xiao S, Yu C, Zhang C, Zhan J, Liu Y et al (2024) Cerebral hemodynamics underlying ankle force sense modulated by high-definition transcranial direct current stimulation. Cereb Cortex. https:\/\/doi.org\/10.1093\/cercor\/bhae226","journal-title":"Cereb Cortex"},{"key":"11114_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-024-01208-4","author":"D Yin","year":"2024","unstructured":"Yin D, Zhong Y, Ling S, Lu S, Wang X, Jiang Z et al (2024) Dendritic-cell-targeting virus-like particles as potent mRNA vaccine carriers. Nat Biomed Eng. https:\/\/doi.org\/10.1038\/s41551-024-01208-4","journal-title":"Nat Biomed Eng."},{"issue":"3","key":"11114_CR15","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1111\/cts.12980","volume":"14","author":"S Yamaguchi","year":"2021","unstructured":"Yamaguchi S, Kaneko M, Narukawa M (2021) Approval success rates of drug candidates based on target, action, modality, application, and their combinations. Clin Transl Sci 14(3):1113\u20131122","journal-title":"Clin Transl Sci"},{"issue":"7","key":"11114_CR16","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1038\/s41380-023-02079-y","volume":"28","author":"Y Du","year":"2023","unstructured":"Du Y, Chen L, Yan MC, Wang YL, Zhong XL, Xv CX et al (2023) Neurometabolite levels in the brains of patients with autism spectrum disorders: a meta-analysis of proton magnetic resonance spectroscopy studies (N= 1501). Mol Psychiatry 28(7):3092\u20133103","journal-title":"Mol Psychiatry"},{"issue":"2","key":"11114_CR17","first-page":"141","volume":"2","author":"X Wang","year":"2019","unstructured":"Wang X, Zhang H, Chen X (2019) Drug resistance and combating drug resistance in cancer. Cancer Drug Resistance 2(2):141","journal-title":"Cancer Drug Resistance"},{"issue":"3","key":"11114_CR18","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.trecan.2019.02.003","volume":"5","author":"N Chatterjee","year":"2019","unstructured":"Chatterjee N, Bivona TG (2019) Polytherapy and targeted cancer drug resistance. Trends Cancer 5(3):170\u2013182","journal-title":"Trends Cancer"},{"issue":"7782","key":"11114_CR19","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","volume":"575","author":"N Vasan","year":"2019","unstructured":"Vasan N, Baselga J, Hyman DM (2019) A view on drug resistance in cancer. Nature 575(7782):299\u2013309","journal-title":"Nature"},{"issue":"23","key":"11114_CR20","doi-asserted-by":"publisher","first-page":"38022","DOI":"10.18632\/oncotarget.16723","volume":"8","author":"RB Mokhtari","year":"2017","unstructured":"Mokhtari RB, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B et al (2017) Combination therapy in combating cancer. Oncotarget 8(23):38022","journal-title":"Oncotarget"},{"issue":"W1","key":"11114_CR21","doi-asserted-by":"publisher","first-page":"W174","DOI":"10.1093\/nar\/gkab438","volume":"49","author":"S Zheng","year":"2021","unstructured":"Zheng S, Aldahdooh J, Shadbahr T, Wang Y, Aldahdooh D, Bao J et al (2021) DrugComb update: a more comprehensive drug sensitivity data repository and analysis portal. Nucleic Acids Res 49(W1):W174\u2013W184","journal-title":"Nucleic Acids Res"},{"issue":"9992","key":"11114_CR22","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","volume":"386","author":"GV Long","year":"2015","unstructured":"Long GV, Stroyakovskiy D, Gogas H, Levchenko E, De Braud F, Larkin J et al (2015) Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386(9992):444\u2013451","journal-title":"Lancet"},{"issue":"9","key":"11114_CR23","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1021\/acs.jmedchem.8b01610","volume":"62","author":"P Das","year":"2018","unstructured":"Das P, Delost MD, Qureshi MH, Smith DT, Njardarson JT (2018) A survey of the structures of US FDA approved combination drugs. J Med Chem 62(9):4265\u20134311","journal-title":"J Med Chem"},{"issue":"5","key":"11114_CR24","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.7150\/jca.49174","volume":"12","author":"X Ma","year":"2021","unstructured":"Ma X, Zhang Y, Wang S, Wei H, Yu J (2021) Immune checkpoint inhibitor (ICI) combination therapy compared to monotherapy in advanced solid cancer: a systematic review. J Cancer 12(5):1318","journal-title":"J Cancer"},{"issue":"6216","key":"11114_CR25","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1126\/science.1254721","volume":"346","author":"AS Crystal","year":"2014","unstructured":"Crystal AS, Shaw AT, Sequist LV, Friboulet L, Niederst MJ, Lockerman EL et al (2014) Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 346(6216):1480\u20131486","journal-title":"Science"},{"issue":"1","key":"11114_CR26","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/s41467-019-09186-x","volume":"10","author":"F Cheng","year":"2019","unstructured":"Cheng F, Kov\u00e1cs IA, Barab\u00e1si AL (2019) Network-based prediction of drug combinations. Nat Commun 10(1):1197","journal-title":"Nat Commun"},{"key":"11114_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.633344","volume":"8","author":"J Buck","year":"2021","unstructured":"Buck J, Dyer PJC, Hii H, Carline B, Kuchibhotla M, Byrne J et al (2021) Veliparib is an effective radiosensitizing agent in a preclinical model of medulloblastoma. Front Mol Biosci 8:633344","journal-title":"Front Mol Biosci"},{"key":"11114_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae072","author":"R Rahman","year":"2024","unstructured":"Rahman R, Shi DD, Reitman ZJ, Hamerlik P, de Groot JF, Haas-Kogan DA et al (2024) DNA damage response in brain tumors: a society for neuro-oncology consensus review on mechanisms and translational efforts in neuro-oncology. Neuro Oncol. https:\/\/doi.org\/10.1093\/neuonc\/noae072","journal-title":"Neuro Oncol"},{"issue":"6","key":"11114_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/or.2023.8562","volume":"49","author":"M Lukoseviciute","year":"2023","unstructured":"Lukoseviciute M, Theodosopoulou A, Holzhauser S, Dalianis T, Kostopoulou ON (2023) Combination of PARP and WEE1 inhibitors in vitro: potential for use in the treatment of SHH medulloblastoma. Oncol Rep 49(6):1\u20139","journal-title":"Oncol Rep"},{"issue":"1","key":"11114_CR30","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41420-024-01814-w","volume":"10","author":"S Karnan","year":"2024","unstructured":"Karnan S, Hanamura I, Ota A, Vu LQ, Uchino K, Horio T et al (2024) ARK5 enhances cell survival associated with mitochondrial morphological dynamics from fusion to fission in human multiple myeloma cells. Cell Death Discov 10(1):56","journal-title":"Cell Death Discov"},{"issue":"3","key":"11114_CR31","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3390\/cancers16030535","volume":"16","author":"P Atalay","year":"2024","unstructured":"Atalay P, Ozpolat B (2024) PIM3 kinase: a promising novel target in solid cancers. Cancers 16(3):535","journal-title":"Cancers"},{"issue":"1","key":"11114_CR32","doi-asserted-by":"publisher","first-page":"20240981","DOI":"10.1515\/med-2024-0981","volume":"19","author":"SA Richard","year":"2024","unstructured":"Richard SA (2024) Advances in synthetic lethality modalities for glioblastoma multiforme. Open Med 19(1):20240981","journal-title":"Open Med"},{"issue":"4","key":"11114_CR33","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/s41388-019-1021-1","volume":"39","author":"F Weinberg","year":"2020","unstructured":"Weinberg F, Griffin R, Fr\u00f6hlich M, Heining C, Braun S, Spohr C et al (2020) Identification and characterization of a BRAF fusion oncoprotein with retained autoinhibitory domains. Oncogene 39(4):814\u2013832. https:\/\/doi.org\/10.1038\/s41388-019-1021-1","journal-title":"Oncogene"},{"issue":"10","key":"11114_CR34","doi-asserted-by":"publisher","first-page":"4053","DOI":"10.7150\/ijbs.73009","volume":"18","author":"Y Wang","year":"2022","unstructured":"Wang Y, Xie Y, Dong B, Xue W, Chen S, Mitsuo S et al (2022) The TTYH3\/MK5 positive feedback loop regulates tumor progression via GSK3-\u03b2\/\u03b2-catenin signaling in HCC. Int J Biol Sci 18(10):4053","journal-title":"Int J Biol Sci"},{"issue":"1","key":"11114_CR35","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.gene.2004.05.028","volume":"340","author":"J Chen","year":"2004","unstructured":"Chen J, Xu J, Ying K, Cao G, Hu G, Wang L et al (2004) Molecular cloning and characterization of a novel human BTB domain-containing gene, BTBD10, which is down-regulated in glioma. Gene 340(1):61\u201369. https:\/\/doi.org\/10.1016\/j.gene.2004.05.028","journal-title":"Gene"},{"issue":"6","key":"11114_CR36","doi-asserted-by":"publisher","first-page":"bbab293","DOI":"10.1093\/bib\/bbab293","volume":"22","author":"B G\u00fcven\u00e7 Paltun","year":"2021","unstructured":"G\u00fcven\u00e7 Paltun B, Kaski S, Mamitsuka H (2021) Machine learning approaches for drug combination therapies. Brief Bioinform 22(6):bbab293","journal-title":"Brief Bioinform"},{"issue":"1","key":"11114_CR37","doi-asserted-by":"publisher","first-page":"bbab355","DOI":"10.1093\/bib\/bbab355","volume":"23","author":"L Wu","year":"2022","unstructured":"Wu L, Wen Y, Leng D, Zhang Q, Dai C, Wang Z et al (2022) Machine learning methods, databases and tools for drug combination prediction. Brief Bioinform 23(1):bbab355","journal-title":"Brief Bioinform"},{"key":"11114_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2022.100110","volume":"3","author":"D Duarte","year":"2022","unstructured":"Duarte D, Vale N (2022) Evaluation of synergism in drug combinations and reference models for future orientations in oncology. Curr Res Pharmacol Drug Discov 3:100110","journal-title":"Curr Res Pharmacol Drug Discov"},{"issue":"3","key":"11114_CR39","doi-asserted-by":"publisher","first-page":"bbac075","DOI":"10.1093\/bib\/bbac075","volume":"23","author":"A Torkamannia","year":"2022","unstructured":"Torkamannia A, Omidi Y, Ferdousi R (2022) A review of machine learning approaches for drug synergy prediction in cancer. Brief Bioinform 23(3):bbac075","journal-title":"Brief Bioinform"},{"issue":"6","key":"11114_CR40","doi-asserted-by":"publisher","first-page":"bbab271","DOI":"10.1093\/bib\/bbab271","volume":"22","author":"K Fan","year":"2021","unstructured":"Fan K, Cheng L, Li L (2021) Artificial intelligence and machine learning methods in predicting anti-cancer drug combination effects. Brief Bioinform 22(6):bbab271","journal-title":"Brief Bioinform"},{"issue":"9","key":"11114_CR41","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1093\/bioinformatics\/btx806","volume":"34","author":"K Preuer","year":"2018","unstructured":"Preuer K, Lewis RP, Hochreiter S, Bender A, Bulusu KC, Klambauer G (2018) DeepSynergy: predicting anti-cancer drug synergy with Deep Learning. Bioinformatics 34(9):1538\u20131546","journal-title":"Bioinformatics"},{"key":"11114_CR42","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/978-1-0716-0849-4_12","volume-title":"Translational bioinformatics for therapeutic development","author":"T Zhang","year":"2021","unstructured":"Zhang T, Zhang L, Payne PR, Li F (2021) Synergistic drug combination prediction by integrating multiomics data in deep learning models. In: Markowitz J (ed) Translational bioinformatics for therapeutic development. Springer, New York, pp 223\u2013238"},{"issue":"4","key":"11114_CR43","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1109\/TCBB.2021.3086702","volume":"19","author":"HI Kuru","year":"2021","unstructured":"Kuru HI, Tastan O, Cicek AE (2021) MatchMaker: a deep learning framework for drug synergy prediction. IEEE\/ACM Trans Comput Biol Bioinf 19(4):2334\u20132344","journal-title":"IEEE\/ACM Trans Comput Biol Bioinf"},{"key":"11114_CR44","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3389\/fphar.2015.00181","volume":"6","author":"J Tang","year":"2015","unstructured":"Tang J, Wennerberg K, Aittokallio T (2015) What is synergy? The Saariselk\u00e4 agreement revisited. Front Pharmacol 6:181","journal-title":"Front Pharmacol"},{"key":"11114_CR45","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/978-1-4939-7154-1_30","volume-title":"Kinase signaling networks","author":"J Tang","year":"2017","unstructured":"Tang J (2017) Informatics approaches for predicting, understanding, and testing cancer drug combinations. In: Tan AC, Huang PH (eds) Kinase signaling networks. Springer, New York, pp 485\u2013506"},{"key":"11114_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2022.105409","volume":"145","author":"Y Su","year":"2022","unstructured":"Su Y, Tian X, Gao R, Guo W, Chen C, Chen C et al (2022) Colon cancer diagnosis and staging classification based on machine learning and bioinformatics analysis. Comput Biol Med 145:105409","journal-title":"Comput Biol Med"},{"issue":"D1","key":"11114_CR47","first-page":"D871","volume":"48","author":"H Liu","year":"2020","unstructured":"Liu H, Zhang W, Zou B, Wang J, Deng Y, Deng L (2020) DrugCombDB: a comprehensive database of drug combinations toward the discovery of combinatorial therapy. Nucleic Acids Res 48(D1):D871\u2013D881","journal-title":"Nucleic Acids Res"},{"issue":"W1","key":"11114_CR48","doi-asserted-by":"publisher","first-page":"W494","DOI":"10.1093\/nar\/gkaa421","volume":"48","author":"H Seo","year":"2020","unstructured":"Seo H, Tkachuk D, Ho C, Mammoliti A, Rezaie A, Madani Tonekaboni SA et al (2020) SYNERGxDB: an integrative pharmacogenomic portal to identify synergistic drug combinations for precision oncology. Nucleic Acids Res 48(W1):W494\u2013W501","journal-title":"Nucleic Acids Res"},{"key":"11114_CR49","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s11030-018-9839-y","volume":"22","author":"L Kang","year":"2018","unstructured":"Kang L, Gao XH, Liu HR, Men X, Wu HN, Cui PW et al (2018) Structure\u2013activity relationship investigation of coumarin\u2013chalcone hybrids with diverse side-chains as acetylcholinesterase and butyrylcholinesterase inhibitors. Mol Divers 22:893\u2013906","journal-title":"Mol Divers"},{"issue":"3","key":"11114_CR50","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","volume":"26","author":"CI Bliss","year":"1939","unstructured":"Bliss CI (1939) The toxicity of poisons applied jointly 1. Ann Appl Biol 26(3):585\u2013615","journal-title":"Ann Appl Biol"},{"issue":"6","key":"11114_CR51","first-page":"285","volume":"3","author":"S Loewe","year":"1953","unstructured":"Loewe S (1953) The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 3(6):285\u2013290","journal-title":"Arzneimittelforschung"},{"key":"11114_CR52","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","volume":"13","author":"B Yadav","year":"2015","unstructured":"Yadav B, Wennerberg K, Aittokallio T, Tang J (2015) Searching for drug synergy in complex dose\u2013response landscapes using an interaction potency model. Comput Struct Biotechnol J 13:504\u2013513","journal-title":"Comput Struct Biotechnol J"},{"issue":"2","key":"11114_CR53","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0031-6997(25)00026-2","volume":"41","author":"MC Berenbaum","year":"1989","unstructured":"Berenbaum MC (1989) What is synergy? Pharmacol Rev 41(2):93\u2013141","journal-title":"Pharmacol Rev"},{"key":"11114_CR54","doi-asserted-by":"publisher","first-page":"giac087","DOI":"10.1093\/gigascience\/giac087","volume":"11","author":"AJ Preto","year":"2022","unstructured":"Preto AJ, Matos-Filipe P, Mour\u00e3o J, Moreira IS (2022) SYNPRED: prediction of drug combination effects in cancer using different synergy metrics and ensemble learning. GigaScience. 11:giac087","journal-title":"GigaScience."},{"key":"11114_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106830","volume":"194","author":"J-B Zhou","year":"2023","unstructured":"Zhou J-B, Tang D, He L, Lin S, Lei JH, Sun H et al (2023) Machine learning model for anti-cancer drug combinations: analysis, prediction, and validation. Pharmacol Res 194:106830","journal-title":"Pharmacol Res"},{"issue":"W1","key":"11114_CR56","doi-asserted-by":"publisher","first-page":"W43","DOI":"10.1093\/nar\/gkz337","volume":"47","author":"B Zagidullin","year":"2019","unstructured":"Zagidullin B, Aldahdooh J, Zheng S, Wang W, Wang Y, Saad J et al (2019) DrugComb: an integrative cancer drug combination data portal. Nucleic Acids Res 47(W1):W43\u2013W51","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"11114_CR57","doi-asserted-by":"publisher","first-page":"17877","DOI":"10.1038\/s41598-022-22324-8","volume":"12","author":"G De Simone","year":"2022","unstructured":"De Simone G, Sardina DS, Gulotta MR, Perricone U (2022) KUALA: A machine learning-driven framework for kinase inhibitors repositioning. Sci Rep 12(1):17877","journal-title":"Sci Rep"},{"issue":"02","key":"11114_CR58","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1055\/a-2235-8845","volume":"74","author":"A Poustforoosh","year":"2024","unstructured":"Poustforoosh A, Faramarz S, Nematollahi MH, Mahmoodi M, Azadpour M (2024) Correction: Structure-based drug design for targeting IRE1: an in silico approach for treatment of cancer. Drug Res 74(02):e1","journal-title":"Drug Res"},{"key":"11114_CR59","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.jconrel.2022.02.015","volume":"343","author":"A Poustforoosh","year":"2022","unstructured":"Poustforoosh A, Nematollahi MH, Hashemipour H, Pardakhty A (2022) Recent advances in Bio-conjugated nanocarriers for crossing the Blood-Brain Barrier in (pre-)clinical studies with an emphasis on vesicles. J Control Release 343:777\u2013797. https:\/\/doi.org\/10.1016\/j.jconrel.2022.02.015","journal-title":"J Control Release"},{"key":"11114_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.molliq.2024.125338","volume":"408","author":"A Poustforoosh","year":"2024","unstructured":"Poustforoosh A (2024) The impact of cationic\/anionic ratio on the physicochemical aspects of catanionic niosomes as a promising carrier for anticancer drugs. J Mol Liq 408:125338. https:\/\/doi.org\/10.1016\/j.molliq.2024.125338","journal-title":"J Mol Liq"},{"key":"11114_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfa.2024.133547","volume":"687","author":"A Poustforoosh","year":"2024","unstructured":"Poustforoosh A (2024) Investigation on the structural and dynamical properties of cationic, anionic, and catanionic niosomes as multifunctional controlled drug delivery system for cabozantinib. Colloids Surf A 687:133547. https:\/\/doi.org\/10.1016\/j.colsurfa.2024.133547","journal-title":"Colloids Surf A"},{"key":"11114_CR62","doi-asserted-by":"publisher","DOI":"10.1007\/s12033-024-01307-2","author":"A Poustforoosh","year":"2024","unstructured":"Poustforoosh A (2024) Scaffold hopping method for design and development of potential allosteric AKT inhibitors. Mol Biotechnol. https:\/\/doi.org\/10.1007\/s12033-024-01307-2","journal-title":"Mol Biotechnol"},{"issue":"2","key":"11114_CR63","first-page":"97","volume":"8","author":"N Tzenios","year":"2023","unstructured":"Tzenios N (2023) Obesity as a risk factor for different types of cancer. EPRA Int J Res Dev (IJRD) 8(2):97\u2013100","journal-title":"EPRA Int J Res Dev (IJRD)"},{"issue":"3","key":"11114_CR64","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41573-022-00615-z","volume":"22","author":"H Jin","year":"2023","unstructured":"Jin H, Wang L, Bernards R (2023) Rational combinations of targeted cancer therapies: background, advances and challenges. Nat Rev Drug Discov 22(3):213\u2013234. https:\/\/doi.org\/10.1038\/s41573-022-00615-z","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"11114_CR65","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1038\/s41587-022-01379-y","volume":"40","author":"Z Tatarova","year":"2022","unstructured":"Tatarova Z, Blumberg DC, Korkola JE, Heiser LM, Muschler JL, Schedin PJ et al (2022) A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs. Nat Biotechnol 40(12):1823\u20131833. https:\/\/doi.org\/10.1038\/s41587-022-01379-y","journal-title":"Nat Biotechnol"},{"issue":"4","key":"11114_CR66","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.tibs.2022.12.001","volume":"48","author":"S Xiao","year":"2023","unstructured":"Xiao S, Verkhivker GM, Tao P (2023) Machine learning and protein allostery. Trends Biochem Sci 48(4):375\u2013390","journal-title":"Trends Biochem Sci"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11114-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-025-11114-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11114-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T05:24:57Z","timestamp":1757136297000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-025-11114-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,22]]},"references-count":66,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["11114"],"URL":"https:\/\/doi.org\/10.1007\/s11030-025-11114-9","relation":{},"ISSN":["1381-1991","1573-501X"],"issn-type":[{"value":"1381-1991","type":"print"},{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,22]]},"assertion":[{"value":"30 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}